Abstract
Alzheimer's disease (AD) is characterize with several pathologies this disease, amyloid plaques, composed of the β-amyloid peptide and γ-amyloid peptide are hallmark neuropathological lesions in Alzheimer's disease brain. Indeed, a wealth of evidence suggests that β-amyloid is central to the pathophysiology of AD and is likely to play an early role in this intractable neurodegenerative disorder. AD is the most prevalent form of dementia, and current indications show that twenty-nine million people live with AD worldwide, a figure expected rise exponentially over the coming decades. Clearly, blocking disease progression or, in the best-case scenario, preventing AD altogether would be of benefit in both social and economic terms. However, current AD therapies are merely palliative and only temporarily slow cognitive decline, and treatments that address the underlying pathologic mechanisms of AD are completely lacking. While familial AD (FAD) is caused by autosomal dominant mutations in either amyloid precursor protein (APP) or the presenilin (PS1, PS2) genes. First, we revised Desing, synthesis, and Biological assay of β and γ-secretase inhibitors. Next, we review 2D QSAR, 3D QSAR, CoMFA, CoMSIA and Docking with different compound to find out the structural requirements. Next, we revised QSAR studies using method of Artificial Neural Network (ANN) in order to understand the essential structural requirement for binding with receptor for β and γ-secretase inhibitors.
Keywords: QSAR, CoMSIA, COMFA, Docking, β-secretase inhibitors, γ-secetase inhibitors, Alzheimer's disease (AD)
Current Topics in Medicinal Chemistry
Title:Review of Synthesis, Assay, and Prediction of β and γ-secretase Inhibitors
Volume: 12 Issue: 8
Author(s): Helena Nino, Jose Enrique Rodriguez-Borges, Xerardo Garcia-Mera and Francisco Prado-Prado
Affiliation:
Keywords: QSAR, CoMSIA, COMFA, Docking, β-secretase inhibitors, γ-secetase inhibitors, Alzheimer's disease (AD)
Abstract: Alzheimer's disease (AD) is characterize with several pathologies this disease, amyloid plaques, composed of the β-amyloid peptide and γ-amyloid peptide are hallmark neuropathological lesions in Alzheimer's disease brain. Indeed, a wealth of evidence suggests that β-amyloid is central to the pathophysiology of AD and is likely to play an early role in this intractable neurodegenerative disorder. AD is the most prevalent form of dementia, and current indications show that twenty-nine million people live with AD worldwide, a figure expected rise exponentially over the coming decades. Clearly, blocking disease progression or, in the best-case scenario, preventing AD altogether would be of benefit in both social and economic terms. However, current AD therapies are merely palliative and only temporarily slow cognitive decline, and treatments that address the underlying pathologic mechanisms of AD are completely lacking. While familial AD (FAD) is caused by autosomal dominant mutations in either amyloid precursor protein (APP) or the presenilin (PS1, PS2) genes. First, we revised Desing, synthesis, and Biological assay of β and γ-secretase inhibitors. Next, we review 2D QSAR, 3D QSAR, CoMFA, CoMSIA and Docking with different compound to find out the structural requirements. Next, we revised QSAR studies using method of Artificial Neural Network (ANN) in order to understand the essential structural requirement for binding with receptor for β and γ-secretase inhibitors.
Export Options
About this article
Cite this article as:
Nino Helena, Enrique Rodriguez-Borges Jose, Garcia-Mera Xerardo and Prado-Prado Francisco, Review of Synthesis, Assay, and Prediction of β and γ-secretase Inhibitors, Current Topics in Medicinal Chemistry 2012; 12 (8) . https://dx.doi.org/10.2174/156802612800166774
DOI https://dx.doi.org/10.2174/156802612800166774 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Psychopathological Behaviour and Cognition in Morbid Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Stem Cell Function, Self-Renewal, Heterogeneity, and Regenerative Potential in Skeletal Muscle Stem Cells
Recent Patents on Regenerative Medicine Neuroprotection by Diazoxide in Animal Models for Cerebrovascular Disorders
Vascular Disease Prevention (Discontinued) Neuroprotective Effects of Exercise Treatments After Injury: The Dual Role of Neurotrophic Factors
Current Neuropharmacology Crocin Protects Against Beta-Amyloid Peptide-Induced Apoptosis in PC12 Cells Via the PI3 K Pathway
Current Molecular Pharmacology Sculpted Amphiphilic Liposomal Particles for Modifiable Medicinal Applications
Current Drug Discovery Technologies Malignancy and Radiation-Induced Cardiotoxicity
Cardiovascular & Hematological Disorders-Drug Targets Cognitive Improvement by Photic Stimulation in a Mouse Model of Alzheimer’s Disease
Current Alzheimer Research Discovery of MAO-B Inhibitors - Present Status and Future Directions Part I: Oxygen Heterocycles and Analogs
Mini-Reviews in Medicinal Chemistry Gestational Programming of Offspring Obesity: A Potential Contributor to Alzheimers Disease
Current Alzheimer Research Metabolic Aspects of Prion Diseases: An Overview
Current Drug Targets An Overview on Global Trends in Nanotechnological Approaches for Alzheimer Therapy
Current Drug Metabolism Release of Adenosine and ATP During Ischemia and Epilepsy
Current Neuropharmacology Tau Therapeutic Strategies for the Treatment of Alzheimers Disease
Current Topics in Medicinal Chemistry Apolipoprotein E-mediated Modulation of ADAM10 in Alzheimer's Disease
Current Alzheimer Research Lithium, a Therapy for AD: Current Evidence from Clinical Trials of Neurodegenerative Disorders
Current Alzheimer Research Tacrine Derivatives and Alzheimers Disease
Current Medicinal Chemistry Epigenetic Changes in the Methylation Patterns of KCNQ1 and WT1 after a Weight Loss Intervention Program in Obese Stroke Patients
Current Neurovascular Research A Model on the Induction of Adverse Vascular Long-Term Effects of NSAIDs
Medicinal Chemistry Neuroprotective Methodologies of Co-Enzyme Q10 Mediated Brain Hemorrhagic Treatment: Clinical and Pre-Clinical Findings
CNS & Neurological Disorders - Drug Targets